Y-mAbs Therapeutics, Inc. provided earnings guidance for the year 2024. The company anticipated DANYELZA net product revenues of between $95 million and $100 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.98 USD | -2.68% | -0.99% | +75.66% |
Jun. 05 | Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer | CI |
Jun. 01 | Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.66% | 526M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.58% | 22.78B | |
-10.58% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024